0001125345-21-000054.txt : 20210419
0001125345-21-000054.hdr.sgml : 20210419
20210419183741
ACCESSION NUMBER: 0001125345-21-000054
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210415
FILED AS OF DATE: 20210419
DATE AS OF CHANGE: 20210419
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Spitznagel Thomas
CENTRAL INDEX KEY: 0001675464
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36112
FILM NUMBER: 21835761
MAIL ADDRESS:
STREET 1: 9704 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MACROGENICS INC
CENTRAL INDEX KEY: 0001125345
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9704 MEDICAL CENTER DRIVE
CITY: Rockville
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-251-5172
MAIL ADDRESS:
STREET 1: 9704 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
wf-form4_161887184277337.xml
FORM 4
X0306
4
2021-04-15
0
0001125345
MACROGENICS INC
MGNX
0001675464
Spitznagel Thomas
9704 MEDICAL CENTER DRIVE
ROCKVILLE
MD
20850
0
1
0
0
Sr VP, BPD & Manufacturing
Common Stock
2021-04-15
4
M
0
5000
7.51
A
5000
D
Common Stock
2021-04-15
4
S
0
5000
30.91
D
0
D
Employee stock option (right to buy)
7.51
2021-04-15
4
M
0
5000
7.51
D
2014-03-18
2023-09-17
Common Stock
5000.0
42147
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021.
This transaction was executed in multiple trades at prices ranging from $30.71 to $31.20. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
12.5% of the shares underlying the grant become (or became) exercisable on the date reflected and an additional 6.25% of the shares underlying the grant become (or became) exercisable on the first day of each three-month period thereafter.
/s/ Lynn Cilinski, Attorney-in-Fact
2021-04-19